

Registration number 04488799

Primorose Pharma Limited
Abbreviated accounts
for the year ended 31 July 2008

2

THURSDAY



A25 *AE0BI4ZK* 240
20/11/2008
COMPANIES HOUSE

Primorose Pharma Limited

Contents

	Page
Accountants' report	1
Abbreviated balance sheet	2 - 3
Notes to the financial statements	4 - 5

Primorose Pharma Limited

**Accountants' report on the unaudited financial statements to the directors of
Primorose Pharma Limited**

As described on the balance sheet you are responsible for the preparation of the financial statements for the year ended 31 July 2008 set out on pages 2 to 5 and you consider that the company is exempt from an audit. In accordance with your instructions we have compiled these unaudited financial statements, in order to assist you to fulfil your statutory responsibilities, from the accounting records and information supplied to us.

Fuju & Co.

Fuju & Co

**Unit 2
Forst Hill Industria Estate
Perry Vale
London
SE23 2LX**

Date: 24 October 2008

Primorose Pharma Limited

**Abbreviated balance sheet
as at 31 July 2008**

		2008		2007	
	Notes	£	£	£	£
Fixed assets					
Tangible assets	2		1,271		2,497
Current assets					
Stocks		134,000		159,632	
Debtors		418,319		698,122	
Cash at bank and in hand		2,103		-	
		<u>554,422</u>		<u>857,754</u>	
Creditors: amounts falling due within one year		<u>(500,939)</u>		<u>(824,044)</u>	
Net current assets			<u>53,483</u>		<u>33,710</u>
Net assets			<u>54,754</u>		<u>36,207</u>
Capital and reserves					
Called up share capital	3		80,000		100
Profit and loss account			<u>(25,246)</u>		<u>36,107</u>
Shareholders' funds			<u>54,754</u>		<u>36,207</u>

The directors' statements required by Section 249B(4) are shown on the following page which forms part of this Balance Sheet

The notes on pages 4 to 5 form an integral part of these financial statements.

Primorose Pharma Limited

Abbreviated balance sheet (continued)

**Directors' statements required by Section 249B(4)
for the year ended 31 July 2008**

In approving these abbreviated accounts as directors of the company we hereby confirm

(a) that for the year stated above the company was entitled to the exemption conferred by Section 249A(1) of the Companies Act 1985 ,

(b) that no notice has been deposited at the registered office of the company pursuant to Section 249B(2) requesting that an audit be conducted for the year ended 31 July 2008 and

(c) that we acknowledge our responsibilities for


(1) ensuring that the company keeps accounting records which comply with Section 221, and

(2) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its profit or loss for the year then ended in accordance with the requirements of Section 226 and which otherwise comply with the provisions of the Companies Act relating to financial statements, so far as applicable to the company

These abbreviated accounts are prepared in accordance with the special provisions of Part VII of the Companies Act 1985 relating to small companies

The abbreviated accounts were approved by the Board on 24 October 2008 and signed on its behalf by

Richard Hodges
Director

A handwritten signature in black ink, appearing to read 'R Hodges', is written over the printed name of the director.

The notes on pages 4 to 5 form an integral part of these financial statements.

Primorose Pharma Limited

**Notes to the abbreviated financial statements
for the year ended 31 July 2008**

1. Accounting policies

1.1. Accounting convention

The accounts are prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective June 2002)

1.2. Turnover

Turnover represents the total invoice value, excluding value added tax, of sales made during the year

1.3. Tangible fixed assets and depreciation

Depreciation is provided at rates calculated to write off the cost less residual value of each asset over its expected useful life, as follows

Fixtures, fittings and equipment	25% on reducing balance
Motor vehicles	- 25% straight line

1.4. Stock

Stock is valued at the lower of cost and net realisable value

1.5. Deferred taxation

Provision is made for deferred taxation using the liability method to take account of timing differences between the incidence of income and expenditure for taxation and accounting purposes except to the extent that the directors consider that a liability to taxation is unlikely to materialise

2. Fixed assets

	Tangible fixed assets £
Cost	
At 1 August 2007	4,909
At 31 July 2008	4,909
Depreciation	
At 1 August 2007	2,411
Charge for year	1,227
At 31 July 2008	3,638
Net book values	
At 31 July 2008	1,271
At 31 July 2007	2,498

Primorose Pharma Limited

**Notes to the abbreviated financial statements
for the year ended 31 July 2008**

continued

3. Share capital	2008	2007
	£	£
Authorised		
100,000 Ordinary shares of 1 each	<u>100,000</u>	<u>1,000</u>
Allotted, called up and fully paid		
80,000 Ordinary shares of 1 each	<u>80,000</u>	<u>100</u>